Drug Profile
Research programme: autologous T cell cancer therapeutics - Amgen/Kite Pharma
Alternative Names: CAR T cell therapies - Amgen/Kite Pharma; DLL3 CAR-T cell therapy - Amgen/Kite Pharma; FLT3 CAR-T cell therapy - Amgen/Kite Pharma; KITE-796Latest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator Amgen; Kite Pharma
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Acute myeloid leukaemia; Haematological malignancies; Small cell lung cancer; Solid tumours
Most Recent Events
- 28 May 2022 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in USA (Parenteral)
- 28 May 2022 No recent reports of development identified for preclinical development in Small-cell-lung-cancer in USA (Parenteral)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (Parenteral)